Press Releases

SAN DIEGO, March 30, 2005 – Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health-care industry, has signed an agreement with The University of Texas M. D. Anderson Cancer Center for its Alaris^® System.

 

The Alaris^® System with Guardrails^® Suite MX software is the most comprehensive safety system available for all types of infusions and the only system with the ability to enable pre-configured limits around both total dose and duration of intermittent drug infusions including chemotherapy. The Alaris^® System has demonstrated measurable improvements in patient safety and clinical performance in managing IV medications at the point of care. It is the only system available to offer a modular platform that includes infusion therapy and patient monitoring.

 

“Cardinal Health took the time to really understand our business objectives and make sure we instituted a solution that would meet our long-term IV-medication management needs,” said Jane Kwan, finance manager, department of pharmacy for The University of Texas M. D. Anderson Cancer Center. “One module we are implementing, the Alaris^® Auto-ID module, will allow us to scan the patient’s wristband, clinician’s ID and IV bag prior to administration, which will help improve data capture and safety.”

 

“We’re pleased M. D. Anderson has selected the Alaris^® System as its IV medication management system,” said Carol Zilm, president of the Medication Products business of Cardinal Health. “M. D. Anderson is a world-renowned cancer center, and we’re excited to have the opportunity to supply M. D. Anderson with a solution that will help its clinicians provide even safer care to their oncology patients.”

 

The University of Texas M. D. Anderson Cancer Center is located in Houston on the campus of the Texas Medical Center. It is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. M. D. Anderson has ranked among the nation's top two cancer hospitals in U.S. News and World Report’s 'America's Best Hospitals' survey for 16 years.

 

 

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $75 billion, global company serving the health-care industry with a broad portfolio of products and services.  It manufactures and distributes pharmaceuticals and medical supplies, offers a range of clinical services and develops automation products that improve the management and delivery of supplies and medication for hospitals, physician offices and pharmacies.  Through this diverse offering, Cardinal Health delivers integrated health care solutions that help customers reduce their costs, improve efficiency and deliver better care to patients.  Ranked No. 16 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents.  More information about the company may be found at www.cardinalhealth.com.

 

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.  The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: the costs, difficulties, and uncertainties related to the integration of acquired businesses; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings; the impact of previously announced restatements; difficulties or delays in implementing its global restructuring program; difficulties in opening new facilities or fully utilizing existing capacity; difficulties and uncertainties associated with business model transitions, including the conversion of margin generated from branded pharmaceutical manufacturers to non-contingent consideration; and general economic and market conditions.  Cardinal Health undertakes no obligation to update or revise any forward-looking statement.